Alterations in coagulation in COVID-19

5Citations
Citations of this article
77Readers
Mendeley users who have this article in their library.

Abstract

Infection with the SARS-CoV-2 virus and the development of all manifestations of COVID-19, predisposes to arterial and venous thromboembolic disease. The coagulation system can be activated by various viruses, including SARS-CoV-2. Vascular endothelial damage, added to the development of disseminated intravascular coagulation, affects the prognosis and mortality from this disease. Treatment is aimed at the prevention, early detection and timely interventions of all coagulation disorders generated by COVID-19. The recommended anticoagulant is low molecular weight heparin, taking into account creatinine clearance, and if major invasive procedures will be performed, unfractionated heparin is a safe option.

Cite

CITATION STYLE

APA

Carrillo-Esper, R., Melgar-Bieberach, R. E., Jacinto-Flores, S. A., Tapia-Salazar, M., & Campa-Mendoza, Á. N. (2020). Alterations in coagulation in COVID-19. Cirugia y Cirujanos (English Edition), 88(6), 787–793. https://doi.org/10.24875/CIRU.20000416

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free